Recombinant adenovirus mediated prostate-specific enzyme pro-drug gene therapy regulated by Prostate-Specific Membrane Antigen (PSMA) enhancer/promoter

Journal of Andrology

Volumn 28, Issue 6, 2007, Pages 827-835

  Zeng, Hao ^a,b   Wei, Qiang ^a   Huang, Rui ^b   Chen, Ni ^b   Dong, Qiang ^a   Yang, Yuru ^a   Zhou, Qiao ^a,b  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

Cytosine deaminase; Prostate adenocarcinoma

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ADENOVIRUS VECTOR; EOSIN; FLUCYTOSINE; FLUOROURACIL; HEMATOXYLIN; PROSTATE SPECIFIC MEMBRANE ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL CYCLE ARREST; CELL CYCLE PHASE; CELL CYCLE S PHASE; CELL GROWTH; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOTOXICITY TEST; DOSE RESPONSE; FLOW CYTOMETRY; GENE DIRECTED ENZYME PRODRUG THERAPY; GROWTH INHIBITION; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REPORTER GENE; SENSITIVITY ANALYSIS; STATISTICAL ANALYSIS; TUMOR VOLUME;

ADENOVIRIDAE; ANTIGENS, SURFACE; CELL LINE, TUMOR; CELL SURVIVAL; CYTOMEGALOVIRUS; ENHANCER ELEMENTS (GENETICS); GENE THERAPY; GENES, REPORTER; GLUTAMATE CARBOXYPEPTIDASE II; GREEN FLUORESCENT PROTEINS; HUMANS; MALE; PLASMIDS; PROMOTER REGIONS (GENETICS); PROSTATIC NEOPLASMS; RECOMBINATION, GENETIC; TRANSCRIPTION, GENETIC;

EID: 35848955689     PISSN: 01963635     EISSN: None     Source Type: Journal    
DOI: 10.2164/jandrol.107.002519     Document Type: Article

References (21)

1. Chung-Faye GA, Chen MJ, Green NK, Burton A, Anderson D, Mautner V, Searle PF, Kerr DJ. In vivo gene therapy for colon cancer using adenovirus-mediated, transfer of the fusion gene cytosine deaminase and uracil phosphoribosyltransferase. Gene Ther. 2001;8:1547-1554.
2. Freytag SO, Strieker H, Pegg J, Paielli D, Pradhan DG, Peabody J, DePeralta-Venturina M, Xia X, Brown S, Lu M, Kim JH. Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer. Cancer Res. 2003;63:7497-7506.
3. Huang X, Zhang W, Wakimoto H, Hamada H, Cao X. Adenovirus-mediated tissue-specific cytosine deaminase gene therapy for human hepatocellular carcinoma with different AFP expression levels. J Exp Ther Oncol. 2002;2:100-106.
4. Ichikawa T, Tamiya T, Adachi Y, Ono Y, Matsumoto K, Furuta T, Yoshida Y, Hamada H, Ohmoto T. In vivo efficacy and toxicity of 5-fluorocytosine/cytosine deaminase gene therapy for malignant gliomas mediated by adenovirus. Cancer Gene Ther. 2000;7:74-82.
5. Israeli RS, Powell CT, Corr JG, Fair WR, Heston WDW. Expression of prostate-specific membrane antigen. Cancer Res. 1994;54: 1807-1811.
6. Kraaij R, van Rijswijk AL, Oomen MH, Haisma HJ, Bangma CH. Prostate specific membrane antigen (PSMA) is a tissue-specific target for adenoviral transduction of prostate cancer in vitro. Prostate. 2005;62:253-259.
7. Lee SJ, Kim HS, Yu R, Lee K, Gardner TA, Jung C, Jeng MH, Yeung F, Cheng L, Kao C. Novel prostate-specific promoter derived from PSA and PSMA enhancers. Mol Ther. 2002;6:415-421.
8. Li ZS, Pan X, Xu GM, Cui L, Dai GR, Gong YF, Tu ZX. Killing effects of cytosine deaminase gene mediated by adenovirus vector on human pancreatic cancer cell lines in vitro. Hepatobiliary Pancreat Dis Int. 2003;2:147-151.
9. Miller CR. Williams CR, Buchsbaum DJ, Gillespie GY. Intratumoral 5-fluorouracil produced by cytosine deaminase/5-fluorocytosine gene therapy is effective for experimental human glioblastomas. Cancer Res. 2002;62:773-780.
10. Miyagi T, Koshida K, Hori O, Konaka H, Katoh H, Kitagawa Y, Mizokami A, Egawa M, Ogawa S. Hamada H, Namiki M. Gene therapy for prostate cancer using the cytosine deaminase/uracil phosphoribosyltransferase suicide system. J Gene Med. 2003;5: 30-37.
11. O'Keefe DS, Uchida A, Bacich DJ, Watt FB, Martorana A, Molloy PL, Heston WD. Prostate-specific suicide gene therapy using the prostate-specific membrane antigen promoter and enhancer. Prostate. 2000;45:149-157.
12. Russell WC. Update on adenovirus and its vectors. J Gen Virol. 2000;81:2573-2604.
13. Silver DA, Pellicer I, Fair WR, Heston WDW, CordonCardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res. 1997;3:81-85.
14. Spitzweg C, Zhang S, Bergert ER, Castro MR, McIver B, Heufelder AE, Tindall DJ, Young CY, Morris JC. Prostate-specific antigen (PSA) promoter-driven androgen-inducible expression of sodium iodide symporter in prostate cancer cell lines. Cancer Res. 1999;59: 2136-2141.
15. Tanaka T, Kanai F, Okabe S, Yoshida Y, Wakimoto H, Hamada H, Shiratori Y, Lan K, Ishitobi M, Omata M. Adenovirus-mediated prodrug gene therapy for carcinoembryonic antigen-producing human gastric carcinoma cells in vitro. Cancer Res. 1996;56: 1341-1345.
16. Uchida A, O'Keefe DS, Bacich DJ, Molloy PL, Heston WD. In vivo suicide gene therapy model using a newly discovered prostate-specific membrane antigen promoter/enhancer: a potential alternative approach to androgen deprivation therapy. Urology. 2001;58:132-139.
17. Wright GL Jr, Grob BM, Haley C, Grossman K, Newhall K, Petrylak D, Troyer J, Konchuba A, Schellhammer PF, Moriarty R. Up-regulation of PSMA after androgen-deprivation therapy. Urology. 1996;42:321-324.
18. Xie X, Zhao X, Liu Y, Zhang J, Matusik RJ, Slawin KM, Spencer DM. Adenovirus-mediated tissue-targeted expression of a caspase-9-based artificial death switch for the treatment of prostate cancer. Cancer Res. 2001;61:6795-6804.
19. Xu XF, Zhou SW, Zhang X, Ye ZQ, Zhang JH, Ma X, Zheng T, Li HZ. Prostate androgen-regulated gene: a novel potential target for androgen-independent prostate cancer therapy. Asian J Androl. 2006;8:455-462.
20. Yu DC, Sakamoto GT, Henderson DR. Identification of the transcriptional regulatory sequences of human kallikrein 2 and their use in the construction of calydon virus 764, an attenuated replication competent adenovirus for prostate cancer therapy. Cancer Res. 1999;59:1498-1504.
21. Zeng H, Wu Q, Li H, Wei Q, Lu Y, Li X, Wang F, Zhao F, Ding Z, Yang Y. Construction of prostate-specific expressed recombinant Plasmids with high transcriptional activity of prostate-specific membrane antigen (PSMA) promoter/enhancer. J Androl. 2005; 26:215-221.